Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare...

Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global
Healthcare Unplugged Conference in New York

SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc.
(Nasdaq: TRBN) today announced that executives will present a corporate update
at the upcoming Morgan Stanley Global Healthcare Unplugged Conference to be
held at the Grand Hyatt New York on Sept. 9, 2008. Dr. Peter Thompson,
president, chief executive officer and chairman, and Dr. Scott C. Stromatt,
newly appointed senior vice president and chief medical officer, are scheduled
to present on Tuesday, Sept. 9 at 4:30 p.m. EDT. The presentation will be
available via audio webcast on Trubion's investor website at
investors.trubion.com.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of
novel protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to develop a
variety of first-in-class and best-in-class product candidates, customized for
optimal safety, efficacy and convenience that it believes may offer improved
patient experiences. Trubion's current product candidates are novel
single-chain protein, or SMIP(TM), therapeutics, and are designed using its
custom drug assembly technology. Trubion's product pipeline includes
CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and
inflammatory diseases, developed under the company's Wyeth collaboration.
Trubion's product pipeline also includes Trubion's proprietary product
candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell
malignancies that is currently in Phase 1/2 clinical evaluation. In addition
to Trubion's current product candidates, the company is also developing
additional alliance and proprietary product candidates that build on its
product development experience. More information is available in the investors
section of Trubion's website: investors.trubion.com.
For more information, contact:

Trubion Pharmaceuticals Inc.
Jim DeNike
Senior Director, Corporate Communications
(206) 838-0500
jdenike@trubion.com
http://www.trubion.com

Waggener Edstrom Worldwide Healthcare
Amy Petty
Senior Account Executive
(617) 576-5788
amyp@waggeneredstrom.com

TRBN-G

SOURCE Trubion Pharmaceuticals Inc.

Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, jdenike@trubion.com; or Amy Petty,
Senior Account Executive of Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, amyp@waggeneredstrom.com for Trubion Pharmaceuticals Inc.